Q-Line Biotech Lists at ₹452, Up 28.28%

Q-Line Biotech Ltd, incorporated in 2010 as a developer, manufacturer, and marketer of diverse range of reagents including kits and POC devices, consumables, and in-vitro diagnostics (IVD) equipment for diagnostic healthcare needs with manufacturing segments spanning Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics, and Rapid Tests having annual capacity of 1.4 million kits and 1,200 Selectra Machines serving diagnostic service providers, hospitals, and medical colleges, made a strong debut on NSE SME on Friday, May 29, 2026. The Q-Line Biotech share price opened at ₹452.00 representing premium of 31.78% from issue price of ₹343.00, touched high of ₹460.00 (up 34.11%) before trading around ₹440.00 (up 28.28%).

Q-Line Biotech Listing Details

Q-Line Biotech launched its fresh issue IPO at ₹343 per share with minimum investment of 800 shares costing ₹2,74,400 raising ₹214.48 crore including ₹61.10 crore from anchor investors. The IPO received exceptional response with massive subscription of 102.42 times - retail investors at 71.44 times, NII strongly subscribed at 145.98 times, QIB at 123.94 times.

First-Day Trading Performance

Listing Price: Q-Line Biotech stock price opened at ₹452.00 representing premium of 31.78% from issue price, touched high of ₹460.00 (up 34.11%) before trading around ₹440.00 (up 28.28%), with VWAP at ₹449.87. The strong listing delivered substantial gains for IPO investors with turnover of ₹136.72 crore, traded volume of 30.39 lakh shares, delivery of 99.82%, and market capitalisation of ₹1,026.44 crore against pre-IPO market cap of ₹800.16 crore.

Growth Drivers and Challenges

Growth Drivers:

Diversified IVD Portfolio: Comprehensive product range across Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics, POC Devices, and Rapid Tests serving complete diagnostic healthcare requirements.

Established Manufacturing: Annual capacity of 1.4 million kits and 1,200 Selectra Machines with focus on R&D, reverse engineering, and quality control enabling indigenous manufacturing and import substitution.

Strong 9M FY26 Performance: Revenue of ₹236.50 crore for 9M FY26 (73% of full FY25), PAT of ₹38.69 crore (already exceeding full FY25 PAT of ₹28.13 crore), improved PAT margin of 16.65% and EBITDA margin of 27.64%.

Challenges:

FY25 Profitability Setback: Analyst warns FY25 suffered setback in bottom line following accounting adjustments with PAT declining from ₹34.44 crore in FY24 to ₹28.13 crore in FY25 despite revenue growth.

Leveraged Balance Sheet: Debt-to-equity ratio of 1.06 with borrowings of ₹243.85 crore, significant portion of IPO proceeds (₹90 crore) going towards debt repayment.

Utilisation of IPO Proceeds

Working Capital: ₹93.50 crore for meeting working capital requirements representing bulk of proceeds supporting inventory and operations expansion.

Debt Repayment: ₹90.00 crore for repayment of certain borrowings to deleverage balance sheet.

General Corporate Purposes: ₹5.10 crore.

Financial Performance

Revenue: ₹236.50 crore for 9 months ended December 2025 (73% of full FY25), ₹322.58 crore for FY25, growth from ₹206.45 crore in FY24 and ₹184.81 crore in FY23.

Net Profit: ₹38.69 crore for 9 months FY26 (already exceeding full FY25), ₹28.13 crore in FY25 (declined from ₹34.44 crore in FY24 due to accounting adjustments), ₹32.10 crore in FY23, with post-IPO EPS of ₹22.12 and P/E of 15.51x. Investors tracking Q-Line Biotech share price should note strong 9M FY26 recovery with PAT margin improving to 16.65% and EBITDA margin to 27.64% despite fully priced valuation concerns in diagnostics equipment segment with no listed peers for comparison.